Now, we developed a natural tumor antigen-specific T cell therapy by directly co-culturing MHC+ tumor cells and naïve-T cells supplying with CD28 co-stimulatory activation signals, in which it could be largely generated from peripheral blood without the application of virus and professional antigen presenting cell (APC) (Fig. 1b). The gene discussed is HLA-C; the disease is neoplasm.